Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.035 AUD
−7.18 M AUD
5.32 M AUD
185.45 M
About ORTHOCELL LIMITED
Sector
Industry
CEO
Paul Frederick Anderson
Website
Headquarters
Murdoch
Founded
2006
ISIN
AU000000OCC6
FIGI
BBG006N6HL75
Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OCC is 1.375 AUD — it has decreased by −1.80% in the past 24 hours. Watch ORTHOCELL LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange ORTHOCELL LIMITED stocks are traded under the ticker OCC.
OCC stock has risen by 9.64% compared to the previous week, the month change is a 69.57% rise, over the last year ORTHOCELL LIMITED has showed a 235.37% increase.
We've gathered analysts' opinions on ORTHOCELL LIMITED future price: according to them, OCC price has a max estimate of 0.97 AUD and a min estimate of 0.97 AUD. Watch OCC chart and read a more detailed ORTHOCELL LIMITED stock forecast: see what analysts think of ORTHOCELL LIMITED and suggest that you do with its stocks.
OCC stock is 6.74% volatile and has beta coefficient of −0.10. Track ORTHOCELL LIMITED stock price on the chart and check out the list of the most volatile stocks — is ORTHOCELL LIMITED there?
Today ORTHOCELL LIMITED has the market capitalization of 333.19 M, it has increased by 1.20% over the last week.
Yes, you can track ORTHOCELL LIMITED financials in yearly and quarterly reports right on TradingView.
ORTHOCELL LIMITED is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
OCC net income for the last half-year is −1.95 M AUD, while the previous report showed −5.23 M AUD of net income which accounts for 62.70% change. Track more ORTHOCELL LIMITED financial stats to get the full picture.
No, OCC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ORTHOCELL LIMITED EBITDA is −11.15 M AUD, and current EBITDA margin is −210.03%. See more stats in ORTHOCELL LIMITED financial statements.
Like other stocks, OCC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORTHOCELL LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORTHOCELL LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORTHOCELL LIMITED stock shows the strong buy signal. See more of ORTHOCELL LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.